NASDAQ:BLPH Bellerophon Therapeutics (BLPH) Stock Forecast, Price & News $7.44 +0.61 (+8.93%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$6.81▼$7.4950-Day Range$6.83▼$12.3952-Week Range$0.67▼$12.58Volume62,452 shsAverage Volume139,939 shsMarket Capitalization$77.75 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Bellerophon Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside303.2% Upside$30.00 Price TargetShort InterestHealthy2.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.47Based on 5 Articles This WeekInsider TradingSelling Shares$5.39 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.18) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector230th out of 1,018 stocksPharmaceutical Preparations Industry98th out of 498 stocks 3.5 Analyst's Opinion Consensus RatingBellerophon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Bellerophon Therapeutics has a forecasted upside of 303.2% from its current price of $7.44.Amount of Analyst CoverageBellerophon Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.30% of the outstanding shares of Bellerophon Therapeutics have been sold short.Short Interest Ratio / Days to CoverBellerophon Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bellerophon Therapeutics has recently increased by 2.04%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBellerophon Therapeutics does not currently pay a dividend.Dividend GrowthBellerophon Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBellerophon Therapeutics has received a 77.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for pulmonary hearth diseases" and "Clinical research services for hypertension" products. See details.Environmental SustainabilityThe Environmental Impact score for Bellerophon Therapeutics is -0.86. Previous Next 1.9 News and Social Media Coverage News SentimentBellerophon Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bellerophon Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 14 people have searched for BLPH on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bellerophon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,392,150.00 in company stock.Percentage Held by Insiders24.70% of the stock of Bellerophon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.36% of the stock of Bellerophon Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bellerophon Therapeutics are expected to grow in the coming year, from ($1.18) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bellerophon Therapeutics is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bellerophon Therapeutics is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBellerophon Therapeutics has a P/B Ratio of 7.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bellerophon Therapeutics (NASDAQ:BLPH) StockBellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.Read More Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BLPH Stock News HeadlinesMay 25, 2023 | americanbankingnews.comBobae Kim Sells 9,455 Shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) StockMay 21, 2023 | americanbankingnews.comAnalysts Offer Predictions for Bellerophon Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:BLPH)May 27, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 20, 2023 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Upgraded at StockNews.comMay 20, 2023 | americanbankingnews.comBellerophon Therapeutics, Inc. Expected to Earn Q2 2023 Earnings of ($0.57) Per Share (NASDAQ:BLPH)May 19, 2023 | msn.comLucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losersMay 17, 2023 | finance.yahoo.comBellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year, surging 18% in the last week aloneMay 16, 2023 | finanznachrichten.deBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 27, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 15, 2023 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseMay 11, 2023 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at LaidlawMay 9, 2023 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Cut to Sell at StockNews.comMay 1, 2023 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Upgraded to Hold at StockNews.comApril 28, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should KnowApril 24, 2023 | finance.yahoo.comBellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?April 19, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should KnowApril 13, 2023 | msn.comBellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should KnowApril 8, 2023 | americanbankingnews.comBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Expected to Post Q1 2023 Earnings of ($0.47) Per ShareApril 7, 2023 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Bellerophon Therapeutics (NASDAQ:BLPH)April 4, 2023 | msn.comHC Wainwright & Co. Reiterates Bellerophon Therapeutics (BLPH) Buy RecommendationApril 4, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Bellerophon (BLPH)April 3, 2023 | finance.yahoo.comWhen Will Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Turn A Profit?April 2, 2023 | seekingalpha.comBellerophon Therapeutics GAAP EPS of -$2.08 misses by $0.06March 31, 2023 | finanznachrichten.deBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial ResultsMarch 31, 2023 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial ResultsMarch 30, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BLPH Company Calendar Last Earnings3/31/2023Today5/27/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLPH CUSIPN/A CIK1600132 Webwww.bellerophon.com Phone(908) 574-4770FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+303.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,830,000.00 Net MarginsN/A Pretax Margin-267.06% Return on Equity-154.00% Return on Assets-93.25% Debt Debt-to-Equity RatioN/A Current Ratio2.94 Quick Ratio2.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book7.37Miscellaneous Outstanding Shares10,450,000Free Float7,869,000Market Cap$77.75 million OptionableNot Optionable Beta0.89 Key ExecutivesPeter FernandesChief Executive, Financial & Accounting OfficerParag Suresh ShahVice President-Business OperationsMartin DekkerVice President-Engineering & ManufacturingEdwin L. ParsleyChief Medical OfficerBobae KimVP-Regulatory Affairs & Quality AssuranceKey CompetitorsHookipa PharmaNASDAQ:HOOKTiziana Life SciencesNASDAQ:TLSAPieris PharmaceuticalsNASDAQ:PIRSEliem TherapeuticsNASDAQ:ELYMCleneNASDAQ:CLNNView All CompetitorsInsiders & InstitutionsLife Science Opportu PuissanceSold 560,000 sharesTotal: $5.30 M ($9.46/share)Bobae KimSold 9,455 sharesTotal: $94,550.00 ($10.00/share)Perceptive Advisors LLCBought 930,000 shares on 5/16/2023Ownership: 8.900%Geode Capital Management LLCBought 31,460 shares on 5/16/2023Ownership: 0.915%State Street CorpBought 8,800 shares on 5/16/2023Ownership: 0.288%View All Insider TransactionsView All Institutional Transactions BLPH Stock - Frequently Asked Questions Should I buy or sell Bellerophon Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLPH shares. View BLPH analyst ratings or view top-rated stocks. What is Bellerophon Therapeutics' stock price forecast for 2023? 2 brokers have issued 12-month target prices for Bellerophon Therapeutics' shares. Their BLPH share price forecasts range from $30.00 to $30.00. On average, they expect the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 303.2% from the stock's current price. View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts. How have BLPH shares performed in 2023? Bellerophon Therapeutics' stock was trading at $0.90 at the beginning of 2023. Since then, BLPH shares have increased by 726.7% and is now trading at $7.44. View the best growth stocks for 2023 here. When is Bellerophon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our BLPH earnings forecast. How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its earnings results on Friday, March, 31st. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.05. When did Bellerophon Therapeutics' stock split? Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX). When did Bellerophon Therapeutics IPO? (BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. What is Bellerophon Therapeutics' stock symbol? Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH." Who are Bellerophon Therapeutics' major shareholders? Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.90%), Renaissance Technologies LLC (1.63%), BlackRock Inc. (0.92%), Geode Capital Management LLC (0.92%), State Street Corp (0.29%) and Dimensional Fund Advisors LP (0.13%). Insiders that own company stock include Bobae Kim, Life Science Opportu Puissance, New Mountain Investments Ii, L and Wassim Fares. View institutional ownership trends. How do I buy shares of Bellerophon Therapeutics? Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bellerophon Therapeutics' stock price today? One share of BLPH stock can currently be purchased for approximately $7.44. How much money does Bellerophon Therapeutics make? Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $77.75 million. The biotechnology company earns $-19,830,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. How can I contact Bellerophon Therapeutics? Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com. This page (NASDAQ:BLPH) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.